Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.

ABSTRACT:

Background

In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA). Treatment with the direct oral thrombin inhibitor dabigatran appears to be associated with a reduced risk of HMB compared with VKA. These findings come from small observational studies or post hoc analyses of trials in which HMB was not a primary outcome. Use of tranexamic acid during the menstrual period may be effective in patients with HMB, but prospective data regarding efficacy and safety in patients on anticoagulant treatment are lacking.

Rationale and design

A direct comparison of a factor Xa inhibitor and a thrombin inhibitor with HMB as primary outcome, as well as an evalu

SUBMITTER: Hamulyak EN 

PROVIDER: S-EPMC7845056 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature